S
Simon Bond
Researcher at Cambridge University Hospitals NHS Foundation Trust
Publications - 75
Citations - 2647
Simon Bond is an academic researcher from Cambridge University Hospitals NHS Foundation Trust. The author has contributed to research in topics: Randomized controlled trial & Clinical trial. The author has an hindex of 24, co-authored 68 publications receiving 2049 citations. Previous affiliations of Simon Bond include University of Cambridge & Mount Vernon Hospital.
Papers
More filters
Journal ArticleDOI
Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial
Katherine Anagnostou,Sabita Islam,Y. King,Loraine Foley,Laura Pasea,Simon Bond,Simon Bond,Christopher R. Palmer,John Deighton,Pamela Ewan,Andrew Clark +10 more
TL;DR: OIT successfully induced desensitisation in most children within the study population with peanut allergy of any severity, with a clinically meaningful increase in peanut threshold.
Journal ArticleDOI
Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response.
TL;DR: There was evidence of a dose-response relationship between increasing protocol prescribed radiotherapy, 5FU and cisplatin dose and pCR and the probability of pCR improved with increasing dose of radiotherapy.
Journal ArticleDOI
Predictors for radiological damage in psoriatic arthritis: results from a single centre
TL;DR: The number of actively inflamed joints, particularly the number of swollen joints, was associated with the progression of radiological damage, and patients with PsA need to be treated, even in the presence of damage as long as there is evidence of inflammation, to preventThe progression of damage.
Journal ArticleDOI
Radiotherapy-related early morbidity in head and neck cancer: quantitative clinical radiobiology as deduced from the CHART trial.
TL;DR: In this paper, the authors quantify the dependence of early reactions on the dose-fractionation used in radiotherapy and on patients' age and radiation field size, using linear regression to analyze the time with reactions in individual patients.
Journal ArticleDOI
Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial.
John A. Todd,Marina Evangelou,Antony J. Cutler,Marcin L. Pekalski,Neil Walker,Helen Stevens,Linsey Porter,Deborah J. Smyth,Daniel B. Rainbow,Ricardo C. Ferreira,Laura Esposito,Kara Hunter,Kevin W. Loudon,Kathryn Irons,Jennie H M Yang,Charles J.M. Bell,Helen Schuilenburg,James Heywood,Ben Challis,Sankalpa Neupane,Pamela Clarke,Gillian Coleman,Sarah Dawson,Donna Goymer,Katerina Anselmiova,Jane Kennet,Judy Brown,Sarah L Caddy,Jia Lu,Jane Greatorex,Ian Goodfellow,Chris Wallace,Timothy Tree,Mark L. Evans,Adrian Mander,Simon Bond,Simon Bond,Linda S. Wicker,Frank Waldron-Lynch +38 more
TL;DR: A statistical and systematic approach was taken by analysing the pharmacokinetics and pharmacodynamics of single doses of subcutaneous aldesleukin in the Adaptive Study of IL-2 Dose on Regulatory T Cells in Type 1 Diabetes, a single centre, non-randomised, open label, adaptive dose-finding trial with 40 adult participants with recently diagnosed T1D.